ProShare Advisors’s Lyell Immunopharma LYEL Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-47,966
| Closed | -$25.8K | – | 2140 |
|
|
2025
Q1 | $25.8K | Sell |
47,966
-10,516
| -18% | -$5.66K | ﹤0.01% | 2018 |
|
|
2024
Q4 | $37.4K | Buy |
58,482
+12,988
| +29% | +$8.31K | ﹤0.01% | 2216 |
|
|
2024
Q3 | $62.8K | Buy |
45,494
+6,512
| +17% | +$8.99K | ﹤0.01% | 1951 |
|
|
2024
Q2 | $56.5K | Sell |
38,982
-10,004
| -20% | -$14.5K | ﹤0.01% | 1735 |
|
|
2024
Q1 | $109K | Buy |
48,986
+4,170
| +9% | +$9.3K | ﹤0.01% | 1808 |
|
|
2023
Q4 | $86.9K | Buy |
44,816
+5,859
| +15% | +$11.4K | ﹤0.01% | 1800 |
|
|
2023
Q3 | $57.3K | Buy |
38,957
+236
| +0.6% | +$347 | ﹤0.01% | 1701 |
|
|
2023
Q2 | $123K | Buy |
38,721
+1,050
| +3% | +$3.34K | ﹤0.01% | 1660 |
|
|
2023
Q1 | $88.9K | Sell |
37,671
-5,213
| -12% | -$12.3K | ﹤0.01% | 1609 |
|
|
2022
Q4 | $149K | Buy |
42,884
+2,963
| +7% | +$10.3K | ﹤0.01% | 1565 |
|
|
2022
Q3 | $293K | Buy |
39,921
+1,315
| +3% | +$9.65K | ﹤0.01% | 1170 |
|
|
2022
Q2 | $251K | Sell |
38,606
-14,133
| -27% | -$91.9K | ﹤0.01% | 1320 |
|
|
2022
Q1 | $267K | Buy |
52,739
+13,726
| +35% | +$69.5K | ﹤0.01% | 1706 |
|
|
2021
Q4 | $302K | Buy |
+39,013
| New | +$302K | ﹤0.01% | 1785 |
|